Added to YB: 2024-06-04
Pitch date: 2024-06-03
IBIO [bullish]
iBio, Inc.
-20.16%
current return
Author Info
Multibagger Monitor focuses on event-driven, reflexive, and microcap situations with the potential to appreciate rapidly in <2 years. Sign up for the newsletter.
Company Info
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Market Cap
$25.3M
Pitch Price
$2.43
Price Target
N/A
Dividend
N/A
EV/EBITDA
1.10
P/E
-1.33
EV/Sales
-41.91
Sector
Biotechnology
Category
growth
10x or Bust? Pure Play Fighting GLP-1 Side Effects ($IBIO)
IBIO: Speculative $20M biotech bet on myostatin inhibitors to spare muscle during GLP-1 weight loss. Key upside: 1) Proven tech (see BIIB/LLY) 2) Aligned team w/ cardiometabolic expertise 3) Recent $15M PIPE at premium to market 4) Upcoming BIIB data as catalyst. Key risks: 1) Cash lasts only to 2026 2) Low probability of success. Potential multi-bagger on positive data or partnership, but very high risk.
Read full article (9 min)